<Page>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Issuer
PURSUANT to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
Filing No. 2 for the Month of August, 2001
Visible Genetics Inc.
(Exact name of Registrant)
700 Bay Street, Suite 1000, Toronto ON, Canada M5G 1Z6
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F
Form 20-F X Form 40-F __
---
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
VISIBLE GENETICS INC.
On March 30, 2000, we entered into an Underwriting Agreement, with
FleetBoston Robertson Stephens Inc., PaineWebber Incorporated, Warburg Dillon
Read LLC and Roth Capital Partners, Inc., as representatives of the several
underwriters named therein. In the underwriting agreement, we agreed to make
generally available to our security holders and the representatives of the
underwriters an earning statement covering the twelve month period ended June
30, 2001 and satisfying the requirements of Section 11(a) of the Securities Act
of 1933, as amended. We hereby submit this Form 6-K and the earning statement
attached hereto as Exhibit 1, in accordance with Section 11(a) of the Securities
Act of 1933, as amended and Rule 158 promulgated thereunder and in satisfaction
of our obligations under the underwriting agreement.
This Form 6-K may contain forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to risks, uncertainties and
other factors which may cause our results to differ materially from
expectations. These include risks relating to the ability to obtain regulatory
approval, market acceptance of genotyping and our products, delays in product
development, delays in making the new Atlanta manufacturing facility
operational, and other risks detailed from time to time in our SEC filings,
including our most recent Annual Report on Form 20-F. These forward-looking
statements speak only as of the date hereof. We disclaim any intent or
obligation to update these forward-looking statements.
Exhibit 1. Earning Statement
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VISIBLE GENETICS INC.
Date: August 10, 2001 By: /s/ THOMAS CLARKE
-----------------
Name: Thomas Clarke
Title: Chief Financial Officer